BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 27159753)

  • 21. Expression of CD44 and variant proteins in human colorectal cancer and its relevance for prognosis.
    Ropponen KM; Eskelinen MJ; Lipponen PK; Alhava E; Kosma VM
    Scand J Gastroenterol; 1998 Mar; 33(3):301-9. PubMed ID: 9548625
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Snail Driving Alternative Splicing of CD44 by ESRP1 Enhances Invasion and Migration in Epithelial Ovarian Cancer.
    Chen L; Yao Y; Sun L; Zhou J; Miao M; Luo S; Deng G; Li J; Wang J; Tang J
    Cell Physiol Biochem; 2017; 43(6):2489-2504. PubMed ID: 29131012
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes and patterns of secondary relapse in platinum-sensitive ovarian cancer: implications for tertiary cytoreductive surgery.
    Tang J; Liu DL; Shu S; Tian WJ; Liu Y; Zang RY
    Eur J Surg Oncol; 2013 Jul; 39(7):786-91. PubMed ID: 23490332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of CD44 and CD24 Expression on 2-years Disease Free Survival in Patients with Advanced Epithelial Ovarian Carcinoma.
    Feharsal Y; Andrijono A; Singoprawiro CS; Lisnawati L; Pakasi TA; Putra AD; Kusuma F; Anggraeni TD; Erlina E; Sarwanti S; Mardhiyah T
    Asian Pac J Cancer Prev; 2024 Feb; 25(2):513-519. PubMed ID: 38415537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Prognostic Value of Cancer Stem Cell Markers (Notch1, ALDH1, and CD44) in Primary Colorectal Carcinoma.
    Mohamed SY; Kaf RM; Ahmed MM; Elwan A; Ashour HR; Ibrahim A
    J Gastrointest Cancer; 2019 Dec; 50(4):824-837. PubMed ID: 30136202
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of c-Src and phospho-Src in epithelial ovarian carcinoma.
    Huang YW; Chen C; Xu MM; Li JD; Xiao J; Zhu XF
    Mol Cell Biochem; 2013 Apr; 376(1-2):73-9. PubMed ID: 23277333
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low Expression of CD44 Is an Independent Factor of Poor Prognosis in Ovarian Mucinous Carcinoma.
    Matuura H; Miyamoto M; Takano M; Soyama H; Aoyama T; Yoshikawa T; Kato K; Sakamoto T; Kuwahara M; Takasaki K; Ishibashi H; Iwahashi H; Tsuda H; Furuya K
    Anticancer Res; 2018 Feb; 38(2):717-722. PubMed ID: 29374695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD44 Immunoexpression is Unfavorable Predictor in Ovarian Serous Cancer.
    Karan Križanac D; Krasić Arapović A; Skočibušić S; Pintarić I; Trgo G; Tomić S
    Appl Immunohistochem Mol Morphol; 2018 Jul; 26(6):398-402. PubMed ID: 27490763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Variant isoforms of CD44 expression in upper tract urothelial cancer as a predictive marker for recurrence and mortality.
    Hagiwara M; Kikuchi E; Kosaka T; Mikami S; Saya H; Oya M
    Urol Oncol; 2016 Aug; 34(8):337.e19-26. PubMed ID: 27133224
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of treatment outcome by CD44v6 after total mesorectal excision in locally advanced rectal cancer.
    Peng J; Lu JJ; Zhu J; Xu Y; Lu H; Lian P; Cai G; Cai S
    Cancer J; 2008; 14(1):54-61. PubMed ID: 18303484
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High expression of epidermal growth factor-like domain 7 is correlated with poor differentiation and poor prognosis in patients with epithelial ovarian cancer.
    Oh J; Park SH; Lee TS; Oh HK; Choi JH; Choi YS
    J Gynecol Oncol; 2014 Oct; 25(4):334-41. PubMed ID: 25142627
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Should epithelial ovarian carcinoma metastatic to the inguinal lymph nodes be assigned stage IVB?
    Nasioudis D; Chapman-Davis E; Frey MK; Caputo TA; Witkin SS; Holcomb K
    Gynecol Oncol; 2017 Oct; 147(1):81-84. PubMed ID: 28716307
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of CD44 and CD44v6 in colorectal carcinoma patients: soluble forms in relation to tumor tissue expression and metastasis.
    Amirghofran Z; Jalali SA; Hosseini SV; Vasei M; Sabayan B; Ghaderi A
    J Gastrointest Cancer; 2008; 39(1-4):73-8. PubMed ID: 19333790
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Expression tumor stem cell surface marker CD44 in gastric cancer and its significance].
    Xie JW; Huang CM; Zheng CH; Li P; Wang JB; Lin JX; Lu J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Nov; 16(11):1107-12. PubMed ID: 24277411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma.
    Liew PL; Hsu CS; Liu WM; Lee YC; Lee YC; Chen CL
    Int J Clin Exp Pathol; 2015; 8(5):5642-9. PubMed ID: 26191276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lymph node metastases as only qualifier for stage IV serous ovarian cancer confers longer survival than other sites of distant disease - a Swedish Gynecologic Cancer Group (SweGCG) study.
    Hjerpe E; Staf C; Dahm-Kähler P; Stålberg K; Bjurberg M; Holmberg E; Borgfeldt C; Tholander B; Hellman K; Kjølhede P; Högberg T; Rosenberg P; Åvall-Lundqvist E
    Acta Oncol; 2018 Mar; 57(3):331-337. PubMed ID: 29130381
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased expression of CD44v6 mRNA significantly correlates with distant metastasis and poor prognosis in gastric cancer.
    Yamamichi K; Uehara Y; Kitamura N; Nakane Y; Hioki K
    Int J Cancer; 1998 Jun; 79(3):256-62. PubMed ID: 9645347
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD44 standard form expression is correlated with high-grade and advanced-stage ovarian carcinoma but not prognosis.
    Zhang J; Chang B; Liu J
    Hum Pathol; 2013 Sep; 44(9):1882-9. PubMed ID: 23664487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns.
    Park JY; Seo SS; Kang S; Lee KB; Lim SY; Choi HS; Park SY
    Gynecol Oncol; 2006 Dec; 103(3):977-84. PubMed ID: 16837030
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic impact of CD44-positive cancer stem-like cells at the invasive front of gastric cancer.
    Kodama H; Murata S; Ishida M; Yamamoto H; Yamaguchi T; Kaida S; Miyake T; Takebayashi K; Kushima R; Tani M
    Br J Cancer; 2017 Jan; 116(2):186-194. PubMed ID: 27931044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.